These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28657917)

  • 1. Patient Registry of Spasticity Care World: Data Analysis Based on Physician Experience.
    Esquenazi A; Lee S; Mayer N; Garreta R; Patel A; Elovic E; Koelbel S; Francisco G; Reuter I;
    Am J Phys Med Rehabil; 2017 Dec; 96(12):881-888. PubMed ID: 28657917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient registry of outcomes in spasticity care.
    Esquenazi A; Mayer N; Lee S; Brashear A; Elovic E; Francisco GE; Yablon S;
    Am J Phys Med Rehabil; 2012 Sep; 91(9):729-46. PubMed ID: 22469872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Muscle Selection for OnabotulinumtoxinA Injections in Poststroke Lower-Limb Spasticity: A Randomized Trial.
    Esquenazi A; Wein TH; Ward AB; Geis C; Liu C; Dimitrova R
    Am J Phys Med Rehabil; 2019 May; 98(5):360-368. PubMed ID: 31003229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).
    Bensmail D; Hanschmann A; Wissel J
    J Med Econ; 2014 Sep; 17(9):618-25. PubMed ID: 24841450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
    Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
    Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach.
    Esquenazi A; Alfaro A; Ayyoub Z; Charles D; Dashtipour K; Graham GD; McGuire JR; Odderson IR; Patel AT; Simpson DM
    PM R; 2017 Oct; 9(10):960-968. PubMed ID: 28286053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity.
    Elovic EP; Munin MC; Kaňovský P; Hanschmann A; Hiersemenzel R; Marciniak C
    Muscle Nerve; 2016 Mar; 53(3):415-21. PubMed ID: 26201835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity.
    Esquenazi A; Bavikatte G; Bandari DS; Jost WH; Munin MC; Tang SFT; Largent J; Adams AM; Zuzek A; Francisco GE
    PM R; 2021 Oct; 13(10):1079-1093. PubMed ID: 33151636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes.
    McCrory P; Turner-Stokes L; Baguley IJ; De Graaff S; Katrak P; Sandanam J; Davies L; Munns M; Hughes A
    J Rehabil Med; 2009 Jun; 41(7):536-44. PubMed ID: 19543664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study.
    Francisco GE; Jost WH; Bavikatte G; Bandari DS; Tang SFT; Munin MC; Largent J; Adams AM; Zuzek A; Esquenazi A
    PM R; 2020 Nov; 12(11):1120-1133. PubMed ID: 31953896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process.
    Simpson DM; Patel AT; Alfaro A; Ayyoub Z; Charles D; Dashtipour K; Esquenazi A; Graham GD; McGuire JR; Odderson I
    PM R; 2017 Feb; 9(2):136-148. PubMed ID: 27346090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial.
    Nam HS; Park YG; Paik NJ; Oh BM; Chun MH; Yang HE; Kim DH; Yi Y; Seo HG; Kim KD; Chang MC; Ryu JH; Lee SU
    J Neurol Sci; 2015 Oct; 357(1-2):192-7. PubMed ID: 26233808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course analysis of the effects of botulinum toxin type a on elbow spasticity based on biomechanic and electromyographic parameters.
    Lee HM; Chen JJ; Wu YN; Wang YL; Huang SC; Piotrkiewicz M
    Arch Phys Med Rehabil; 2008 Apr; 89(4):692-9. PubMed ID: 18374000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study.
    Santamato A; Micello MF; Panza F; Fortunato F; Pilotto A; Giustini A; Testa A; Fiore P; Ranieri M; Spidalieri R
    Eur J Phys Rehabil Med; 2013 Aug; 49(4):483-9. PubMed ID: 23480980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke.
    Pittock SJ; Moore AP; Hardiman O; Ehler E; Kovac M; Bojakowski J; Al Khawaja I; Brozman M; Kanovský P; Skorometz A; Slawek J; Reichel G; Stenner A; Timerbaeva S; Stelmasiak Z; Zifko UA; Bhakta B; Coxon E
    Cerebrovasc Dis; 2003; 15(4):289-300. PubMed ID: 12686794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial.
    Marciniak CM; Harvey RL; Gagnon CM; Duraski SA; Denby FA; McCarty S; Bravi LA; Polo KM; Fierstein KM
    Am J Phys Med Rehabil; 2012 Dec; 91(12):1007-19. PubMed ID: 23064478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronox versus BOTOX in the Treatment of Post-Stroke Upper Limb Spasticity: A Multicenter Randomized Controlled Trial.
    Seo HG; Paik NJ; Lee SU; Oh BM; Chun MH; Kwon BS; Bang MS
    PLoS One; 2015; 10(6):e0128633. PubMed ID: 26030192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: results of the German-Austrian open-label post-marketing surveillance prospective study.
    Jost WH; Hefter H; Reissig A; Kollewe K; Wissel J
    J Neurol Sci; 2014 Feb; 337(1-2):86-90. PubMed ID: 24361062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial.
    Rosales RL; Kong KH; Goh KJ; Kumthornthip W; Mok VC; Delgado-De Los Santos MM; Chua KS; Abdullah SJ; Zakine B; Maisonobe P; Magis A; Wong KS
    Neurorehabil Neural Repair; 2012 Sep; 26(7):812-21. PubMed ID: 22371239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is spastic muscle echo intensity related to the response to botulinum toxin type A in patients with stroke? A cohort study.
    Picelli A; Bonetti P; Fontana C; Barausse M; Dambruoso F; Gajofatto F; Girardi P; Manca M; Gimigliano R; Smania N
    Arch Phys Med Rehabil; 2012 Jul; 93(7):1253-8. PubMed ID: 22502807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.